Replies to post #509 on Outlook Therapeutics Inc (OTLK)

[herbied47]

Hey Evan. Sorry I couldn’t private message a reply back to you. I haven’t used ihub much lately, but as to NISN, hedge fund Sabby has been the reason for the dip, but it has produced the buying opportunity moving forward. Recent announced 8 million share buyback.

[thermo]

Approved earlier this year:

On February 7, 2022, FDA had approved Vabysmo (faricimab-svoa), an injectable therapy for those with wet age-relate macular degeneration (wAMD) and diabetic macular edema. This approval is especially interesting considering that it is the first drug of its kind to be approved for both wAMD and diabetic macular edema.

As I noted, this will be a premium priced product, no different than Eylea.